To clarify the mutation of the ‰avin-containing monooxygenase (FMO) 3 gene causingˆsh-odor syndrome, we analyzed the FMO3 gene of a Thai subject who possibly suŠered fromˆsh-odor syndrome. A novel mutation, a single-base substitution from G to A at the position of 265 (G265A), was identiˆed in exon 3. The mutation caused an amino acid substitution from valine to isoleucine at residue 58 (V58I). The mutated FMO3 protein with V58I exhibited the reduced trimethylamine N-oxidase activity when it was expressed in E. coli. The V max W K m value for the activity of the mutant-type FMO3 was about 5 times lower than that for the wild-type FMO3.
Introduction
The ‰avin-containing monooxygenase (FMO) catalyzes the oxidation of a wide variety of compounds containing a sulfur, nitrogen or phosphorus atom. 1, 2) The proteins and cDNAs of FMO have been isolated from several mammalian species including humans. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Based on the sequence similarity, mammalian FMOs are classied intoˆve isoforms (FMO1-FMO5). 22) Human FMO3 is considered as a major form in adult livers, while human FMO1 is detectable in the kidney and fetal livers, but not in adult livers. 23) It seems that functional proteins of FMO4 are not expressed in humans. 24, 25) There is only a limited knowledge of the physiological roles of human FMOs.
Trimethylamine (TMA) is one of the tertiary amines that are the typical substrates of FMO. 2, 26) TMA is derived from dietary sources such as choline, carnitine, lecithin and TMA N-oxide (TMAO). 27) This chemical exists as a vapor under standard conditions (boiling point, 39 C) and exhibits low olfactory threshold. The reduced capacity to N-oxidize TMA is believed to cause a metabolic disorder known asˆsh-odor syndrome or trimethylaminuria in which patients excrete higher amounts of TMA in the urine, sweat and breath. 28, 29) To clarify the molecular form(s) of FMO responsible for the N-oxidation of TMA, Lang et al. expressed the forms of the enzyme in E. coli and proved that the human FMO3 catalyzed the N-oxidation of TMA, 30) which was in accordance with the previous concept that the deˆciency of FMO3 was the cause ofˆsh-odor syndrome. 31, 32) Recently, patients ofˆsh-odor syndrome were reported in Orientals in addition to Caucasians. 33) The frequency of several mutations in FMO3 gene was analyzed in some Asians. 34, 35) However, the mutation(s) of the FMO3 gene causing theˆsh-odor syndrome in Orientals has not been fully understood. In this paper, we analyzed the FMO3 gene of a possible patient ofˆsh-odor syndrome in Thailand, and found a novel mutation in the gene causing the reduced capacity of TMN Noxidation.
Materials and Methods

Materials
TMA hydrochloride was purchased from Wako Pure Chemicals (Osaka, Japan). TMAO dihydrate was obtained from Aldrich Chemical (Milwaukee, WI). NADPH, NADP + , glucose 6-phosphate and glucose 6- Urinary excretion of TMA and TMAO Urine samples were stored at "809 C until analysis. TMA in the urine was directly analyzed by a head-space gas chromatography, and TMAO was determined indirectly after reduction of TMAO with TiCl3 to generate TMA as previously described.
36) The TMA thus formed was quantiˆed by a gas chromatograph as described above. The amount of TMAO was calculated from the increase in TMA after the chemical reduction.
Sequencing of the FMO3 gene
Peripheral blood samples were collected from normal healthy Thai volunteers and possible patients ofˆsh-odor syndrome. Genomic DNA was extracted from peripheral leukocytes with phenol-chloroform followed by ethanol precipitation. 37) The nine exons and the intron W exon boundaries of the FMO3 gene were ampliˆed by polymerase chain reaction (PCR) with Pfu DNA polymerase (Stratagene, La Jolla, CA). The sense and antisense primer sequences designed from the sequence of the FMO3 gene 38) are shown in Table 1 . The ampliˆed DNA fragments were blunt-ended with T4 DNA polymerase (Takara Shuzo), phosphorylated by T4 polynucleotide kinase (New England Biolabs), and then subcloned into the pBluescript II SK (") (Stratagene). The inserted DNA fragments were sequenced with a Perkin Elmer ABI PRISM TM 377 DNA Sequencer. Mutations were veriˆed by the direct sequencing of PCR products. The nucleotide number is shown according to the sequence of FMO3 cDNA.
23)
Construction of expression plasmids
Human FMO3 cDNA was isolated from human liver total RNA by the reverse transcription PCR. The HindIII site was introduced just downstream of the termination codon of the FMO3 cDNA. The modiˆed FMO3 cDNA was digested with NcoI and HindIII, and then subcloned into pTrc99A (pTHF3). The mutation, G265A, was introduced into the FMO3 cDNA by PCR with Pfu DNA polymerase. An NcoI-SacI fragment from the pTHF3 was subcloned into the pBluescript II SK ("). This plasmid was used as a template. The sequences of the oligonucleotide primers used for mutagenesis are as follows: FMO3m265 (S), 5?-TTACAAATCAATCTTTTCCA-3?; FMO3m265 (AS), 5?-TGGAAAAGATTGATTT-GTAA-3?; M13-21, 5?-TGTAAAACGACGGCCAGT-3?; M13Rev, 5?-CAGGAAACAGCTATGAC-3?. Two PCR products were ampliˆed using two pairs of primers: FMO3m265 (S) and M13Rev, FMO3m265 (AS) and M13-21. The fragment containing the mutated sequences was generated by a second PCR using the two PCR products as templates and the primers M13-21 and M13Rev. This fragment was digested with NcoI and SacI, and then was replaced with the NcoI-SacI fragment of the pTHF3. This plasmid was designated as pTHF3m265. The introduction of mutation was veriˆed by DNA sequencing.
Expression of human FMOs in E. coli E. coli JM105 cells transformed with a plasmid, pTrc99A, pTHF3 or pTHF3m265 were grown with shaking at 379 C in modiˆed Terriˆc Broth containing ampicillin (50 mg W mL). When cell density monitored by absorbance at 600 nm reached 0.8, induction of the protein expression was initiated by addition of isopropyl-1-thio-b-D-galactopyrano-side (1 mM). After a further in- cubation at 309 C for 24 h with shaking, the bacterial membrane fraction was prepared as reported by AttaAsafo-Adjei et al.
11)
Western blot analysis Western blot analysis was performed as described by Itoh et al. 5) Brie‰y, membrane proteins were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) (7.5z gel) according to the method of Laemmli.
39)
Separated proteins were transferred onto an Immobilon membrane (Millipore, Bedford, MA). Rabbit polyclonal antibodies raised to human FMO3, goat antirabbit IgG antibody and peroxidase-conjugated rabbit anti-peroxidase antibody were sequentially added to the membrane. Then the proteins were stained with 3,3?-diaminobenzidine and hydrogen peroxide to visualize the expressed FMO.
Determination of FAD Content
The FAD content was determined ‰uorometrically by the method of Faeder and Siegel. 40) Kinetics of TMA N-oxidation TMA N-oxidation was analyzed as described previously 36) with minor modiˆcations. Brie‰y, a typical reaction mixture consisted of 50 mM Tris-HCl buŠer (pH 8.4), an NADPH generating system (10 mM MgCl2, 10 mM glucose 6-phosphate, 0.4 mM NADP + and 0.5 U W mL glucose 6-phosphate dehydrogenase) and human liver microsomes (0.4 mg W mL protein) or the membrane fraction of E. coli (0.5 mg W mL protein) in aˆnal volume of 0.5 mL. The reaction mixture was preincubated at 379 C for 3 min. The reaction was initiated by the addition of TMA. After incubation for 10 min, 25z (w W v) ZnSO 4 (50 mL) and a saturated aqueous solution of Ba(OH)2 (50 mL) was added to stop the reaction. The mixture was centrifuged at 1,300×g for 5 min. An aliquot (0.4 mL) of the supernatant was transferred to a glass vial, made alkaline with 5 M NaOH (20 mL), and then evaporated to dryness in vacuo at 809 C. The residue was dissolved in 1 M HCl (0.4 mL) followed by the addition of 20z (w W v) TiCl3 (0.1 mL). The TMAO in the sample was reduced in the capped vial at room temperature for 1 h. Immediately after the addition of 10 M NaOH (5 mL), the vial was capped with a te‰on-lined septum and kept at 959 C for 30 min. The headspace gas (0.8 mL) was subjected to a gas chromatograph. To determine kinetic parameters, the TMA concentration ranged from 6.25 to 200 mM for the assay using E. coli membranes. Lineweaver-Burk plots were adapted for the determination of kinetic parameters.
Gas chromatography
GC-17A series gas chromatograph (Shimadzu, Kyoto, Japan) with a ‰ame thermoionic detector was used for the analysis of TMA as described previously.
36)
Results
Urinary excretion of TMA and TMAO in Thai
We investigated the urinary excretion of TMA and TMAO in a Thai subject who possibly suŠered from sh-odor syndrome. The percentage of total TMA excreted as TMAO in this individual was lower than that of a healthy Thai subject ( Table 2 ). This result was in accordance with the fact that the patient had theˆsh-like odor of exhalation.
Sequence analysis of the FMO3 gene of a possible patient
The sequences of all of the nine exons and the intron W exon boundaries of the FMO3 gene were analyzed, because of the possibility that this individual was a heterozygous carrier of the allele for theˆsh-odor syndrome. Thus, we found a single base substitution from G to A at the position of 265 (G265A) in exon 3 (Fig. 1) . This is a novel mutation which has not been reported. The mutation was detected only in an allele of this individual, but not in alleles of normal healthy Thai volunteers. The mutation caused an amino acid substitution from valine to isoleucine at the residue 58 (V58I).
TMA N-oxidase activity of the mutant-type FMO3 expressed in E. coli
To evaluate the eŠects of the substitution of V58I on the TMA N-oxidase activity of FMO3, the mutant-type FMO3 was expressed in E. coli after the mutation was introduced into a wild-type FMO3 cDNA. The expression of the mutant-type FMO3 in E. coli was conˆrmed by Western blot analysis (Fig. 2) . The mutant-type protein was detected at the same mobility with an expression level similar to that of the wild-type protein.
Immunoreactive protein was undetectable in the membranes of E. coli transformed with a vector. The expression level of FMO in the E. coli membranes was estimat- 6 mg) . Membranes prepared from E. coli were separated by SDS-PAGE and then transferred onto a nylon membrane. Rabbit polyclonal antibodies raised to human FMO3 were used for the immunoreaction. Table 3 . The apparent Km value of 50.9 mM for the wild-type FMO3 was comparable to that obtained using human liver microsomes, 45.9 mM. The Vmax W Km value for the mutant-type FMO3 was about 5 times lower than that for the wild-type FMO3.
Analysis of the G265A mutation in Thai subjects The G265A mutation was genotyped by sequencing the FMO3 gene in six normal healthy Thai volunteers and twelve Thai subjects who possibly suŠered from sh-odor syndrome. Another heterozygous carrier of this mutant allele was found among 12 possible patients ofˆsh-odor syndrome.
Discussion
Recently, it was reported that a patient who suŠered fromˆsh-odor syndrome had an FMO3 gene with a mutation or deletion that resulted in reduced activity for TMA oxidation. 31, 32, 41, 42) The Thai subject, a possible patient ofˆsh-odor syndrome, excreted 90.8z of TMA as TMAO, while the percentage of total TMA excreted as TMAO in the urine of patients withˆsh-odor syndrome was reported to be less than 55z under normal dietary conditions in the previous studies. 29, 33, 41, 43) The heterozygotes ofˆsh-odor syndrome showed the saturation of the N-oxidation of TMA at the challenge dose (600 mg) of TMA but not under normal dietary condition. 29, 44) Therefore, we supposed that this individual was a heterozygous carrier of the impaired FMO3 gene. Recently, combinations of some mutations showed a slight decrease in TMA oxidation under normal physiological conditions.
45) The mutation (G265A) found in the FMO3 gene of this individual is a novel mutation that has not been reported. This base replacement results in the amino acid substitution of 58 Val to Ile (V58I). This individual had no other reported mutations and deletions causing a defect of TMA N-oxidase activity. 31, 32, 41, 42, 46) The reported mutations, G291A (M66I), T338C (M82T), C551T (P153L) and G1006T (E305X), resulted in the defect of TMA N-oxidase activity when the mutated proteins were expressed in E. coli or baculovirus-insect cell system. In addition, this individual did not have the mutations of FMO3 gene found in the Korean population. 47) Recently, an additional mutation, G247A (A52T), was found in the FMO3 gene of a North American withˆsh-odor syndrome.
48) Dolphin et al. reported that G275A (N61S), G1395A (M434I) and C1567T (R492W) caused the loss of the capacity to catalyze the N-oxidation of TMA.
49) The V58I mutation was located near the A52T, the N61S and the M66I, suggesting a possibility that the mutation caused a reduction of the enzyme activities. In fact, the FMO3 carrying the V58I mutation exhibited about 5 times lower Vmax W Km value for TMA N-oxidation than the wild-type FMO3 ( Table 3) . The mutation may alter the protein structure of FMO3, though V58 is located neither in the FADnor NADPH-binding domain essential for the function of FMO. The valine residue is conserved in known mammalian FMO isoforms except FMO4 that was not expressed in the heterologous expression systems. 12, 24, 25) The mutation was found only in subjects who possibly suŠered fromˆsh-odor syndrome. The mutation of FMO3 would play a more important role in causing thê sh-odor syndrome if other mutations that reduce the TMA N-oxidase activity exist together.
